Daniel M. Frendl, M.D., Ph.D.

Daniel M. Frendl, M.D., Ph.D., is a urologist with an interest in prostate cancer, benign prostatic hyperplasia, and prostate health. He is a urologic surgeon with a clinical practice that includes:

• Prostate cancer diagnosis: transperineal prostate biopsy with magnetic resonance imaging and ultrasound fusion
• Prostate ablation: Focal treatments for prostate cancer including high intensity focused ultrasound (HIFU), Irreversible electroporation (NanoKnife), and clinical trials for other technologies
• Salvage prostate ablation: Focal ablation of prostate cancer that is locally recurrent after radiation treatment
• SpaceOAR and Barrigel rectal spacer placement for patients undergoing radiation for prostate cancer
• Treatments for benign prostatic hyperplasia: Rezum, UroLift, and transurethral resection (TURP)
• Biopsy and resection of nonmuscle invasive bladder and urothelial cancers
• Inguinal, scrotal, and penile surgery including: hydrocelectomy, orchiectomy, vasectomy, circumcision
• Ureteroscopy

Dr. Frendl is actively recruiting for the following clinical trials of focal therapy for prostate cancer:

• Vapor2: a prospective multi-center, single-arm, clinical trial of transurethral water vapor ablation of Gleason Grade Group 2 (GS 3+4) prostate cancer using minimally invasive VanquishT Water Vapor Ablation. Eligible patients must have disease confined to a region surrounding an MRI visible PIRADS3 or PIRADS4 lesion

Mayo Clinic's Department of Urology is one of the few urology practices in Arizona that routinely performs transperineal prostate biopsies with advanced imaging guidance. Transperineal prostate biopsies enable more accurate detection of prostate cancer and offer a lower risk of infection than traditional transrectal biopsies. Dr. Frendl's practice specializes in the transperineal approach to prostate biopsy as well as focal treatments for prostate cancer.

In addition to his clinical practice, Dr. Frendl is also a health services researcher and is active in health policy advocacy through the American Urological Association. His current research focuses on assessing the efficacy of focal ablation treatments for prostate cancer and quality of life outcomes. Nationally, he is an active member of the Legislative Affairs Committee for the American Urological Association. Dr. Frendl received his M.D. and Ph.D. in Clinical and Population Health Research from the University of Massachusetts Medical School. He completed his training at the Massachusetts General Hospital — Harvard Urologic Surgery Residency Program. Dr. Frendl also completed a fellowship in Healthcare Policy and Administration with the Massachusetts General Hospital Physician's Organization.